Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vitro Diagnostics (VODG : OTCBB)

• Company Description    Vitro Diagnostics is engaged in the research and development of products andtechnology for use in the manufacture of human therapeutic products targeted tothe treatment of specific diseases. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $ Daily Weekly Monthly 20 Day Moving Average: shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 52 Week High: $1.04 52 Week Low: $0.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week % % 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3200 Cherry Creek Drive South Suite 720 - Denver,CO 80209 USA ph: 855-848-7627 fax: 469-633-0088 ir@vitrobiopharma.com http://www.vitrobiopharma.com

• General Corporate Information    Officers Christopher Furman - Chief Executive Officer John Packs - Chair of the Board Nathan Haas - Chief Financial Officer James R. Musick - Director Caroline Mosessian - Director Peer Information Vitro Diagnostics (CORR.) Vitro Diagnostics (RSPI) Vitro Diagnostics (CGXP) Vitro Diagnostics (BGEN) Vitro Diagnostics (GTBP) Vitro Diagnostics (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 928501303 SIC: 2836 Fiscal Year Fiscal Year End: October Last Reported Quarter: 01/01/23 Next Expected EPS Date: - Share - Related Items Shares Outstanding: Most Recent Split Date: (:1) Beta: Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: % Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -70.24% vs. Previous Quarter: -% ROE 04/30/23 - - 01/31/23 - - 10/31/22 - - ROA 04/30/23 - - 01/31/23 - - 10/31/22 - - Current Ratio 04/30/23 - - 01/31/23 - 0.98 10/31/22 - 1.16 Quick Ratio 04/30/23 - - 01/31/23 - 0.88 10/31/22 - 1.05 Operating Margin 04/30/23 - - 01/31/23 - - 10/31/22 - - Net Margin 04/30/23 - - 01/31/23 - - 10/31/22 - - Pre-Tax Margin 04/30/23 - - 01/31/23 - - 10/31/22 - -208.32 Book Value 04/30/23 - - 01/31/23 - - 10/31/22 - - Inventory Turnover 04/30/23 - - 01/31/23 - - 10/31/22 - 2.65 Debt-to-Equity 04/30/23 - - 01/31/23 - 1.65 10/31/22 - 0.97 Debt-to-Capital 04/30/23 - - 01/31/23 - 62.21 10/31/22 - 49.21

Powered by Zacks Investment Research ©